Teva Pharmaceutical Industries (TEVA) EBT (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported EBT for 18 consecutive years, with -$455.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 324.14% year-over-year to -$455.0 million; the trailing twelve-month figure through Jun 2026 stood at $708.0 million (up 1056.76% YoY), and the FY2025 full-year result was $1.2 billion, up 195.25% from the prior year.
• EBT eased to -$455.0 million in Q2 2026 per TEVA's latest filing, from $437.0 million in the prior quarter.
• Across five years, EBT topped out at $646.0 million in Q3 2025 and bottomed at -$1.2 billion in Q4 2022.
• Historically, EBT has averaged -$162.9 million across 5 years, with a median of -$91.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: EBT slumped 774.31% in 2022, then soared 299.38% in 2025.
• Over 5 years, EBT stood at -$1.2 billion in 2022, then jumped by 142.78% to $507.0 million in 2023, then sank by 148.72% to -$247.0 million in 2024, then jumped by 132.39% to $80.0 million in 2025, then sank by 668.75% to -$455.0 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$455.0 million, $437.0 million, and $80.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.